Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income from Continuing Operations (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Income from Continuing Operations data on record, last reported at 16167000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 597.45% year-over-year to 16167000.0; the TTM value through Dec 2025 reached 12606000.0, up 32.16%, while the annual FY2025 figure was 63367000.0, 241.01% down from the prior year.
  • Income from Continuing Operations reached 16167000.0 in Q4 2025 per LCTX's latest filing, up from 3420000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 16167000.0 in Q4 2025 and bottomed at 19326000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 5380157.89, with a median of 6027000.0 recorded in 2025.
  • Peak YoY movement for Income from Continuing Operations: crashed 389.85% in 2022, then surged 597.45% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 8846000.0 in 2021, then crashed by 38.28% to 12232000.0 in 2022, then surged by 61.46% to 4714000.0 in 2023, then surged by 31.06% to 3250000.0 in 2024, then soared by 597.45% to 16167000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 16167000.0 in Q4 2025, 3420000.0 in Q3 2025, and 19326000.0 in Q2 2025.